The Experts below are selected from a list of 1485 Experts worldwide ranked by ideXlab platform
G. Tollefson - One of the best experts on this subject based on the ideXlab platform.
-
The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease.
International Journal of Geriatric Psychiatry, 2001Co-Authors: John S. Kennedy, A. Zagar, Franklin Porter Bymaster, George G. Nomikos, P. T. Trzepacz, J.a. Gilmore, M. D. Rotelli, Alan Breier, G. TollefsonAbstract:Objective The objective of this analysis was to compare the treatment-emergent central anticholinergic-like adverse events experienced during treatment with olanzapine versus placebo in patients with psychosis and/or agitation due to Alzheimer's disease (AD). In addition, changes in cognition were assessed in a subgroup of patients with mild to moderate cognitive impairment. Methods Double-blind data were compared for placebo and three fixed olanzapine dosages (5 mg/day, 10 mg/day, and 15 mg/day) in 206 nursing home-residing patients with AD for five a priori selected central nervous system anticholinergic-like adverse events: confusion, delirium, delusions, hallucinations, Abnormal Thinking. Mean change from baseline to endpoint on the Alzheimer's Disease Assessment Scale—Cognitive (ADAS-Cog) was measured for a subgroup of 43 patients who had mild to moderate cognitive impairment at baseline. Results There were no significant differences in central anticholinergic-like adverse events at any olanzapine dose compared to placebo. Additionally, in the 43-patient subgroup, there were no significant differences in mean change in ADAS-Cog scores between placebo and the three olanzapine dose subgroups. Conclusion Olanzapine did not differ significantly from placebo for any of the five central nervous system anticholinergic events nor on the ADAS-Cog. Olanzapine's initially reported potent in vitro muscarinic receptor affinity is not consistent with this clinical study of central nervous system anticholinergic-like adverse events in patients with AD. Copyright © 2001 John Wiley & Sons, Ltd.
-
The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease.
International journal of geriatric psychiatry, 2001Co-Authors: John S. Kennedy, A. Zagar, Franklin Porter Bymaster, George G. Nomikos, P. T. Trzepacz, J.a. Gilmore, M. D. Rotelli, Alan Breier, G. TollefsonAbstract:The objective of this analysis was to compare the treatment-emergent central anticholinergic-like adverse events experienced during treatment with olanzapine versus placebo in patients with psychosis and/or agitation due to Alzheimer's disease (AD). In addition, changes in cognition were assessed in a subgroup of patients with mild to moderate cognitive impairment. Double-blind data were compared for placebo and three fixed olanzapine dosages (5 mg/day, 10 mg/day, and 15 mg/day) in 206 nursing home-residing patients with AD for five a priori selected central nervous system anticholinergic-like adverse events: confusion, delirium, delusions, hallucinations, Abnormal Thinking. Mean change from baseline to endpoint on the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) was measured for a subgroup of 43 patients who had mild to moderate cognitive impairment at baseline. There were no significant differences in central anticholinergic-like adverse events at any olanzapine dose compared to placebo. Additionally, in the 43-patient subgroup, there were no significant differences in mean change in ADAS-Cog scores between placebo and the three olanzapine dose subgroups. Olanzapine did not differ significantly from placebo for any of the five central nervous system anticholinergic events nor on the ADAS-Cog. Olanzapine's initially reported potent in vitro muscarinic receptor affinity is not consistent with this clinical study of central nervous system anticholinergic-like adverse events in patients with AD. Copyright 2001 John Wiley & Sons, Ltd.
John S. Kennedy - One of the best experts on this subject based on the ideXlab platform.
-
The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease.
International Journal of Geriatric Psychiatry, 2001Co-Authors: John S. Kennedy, A. Zagar, Franklin Porter Bymaster, George G. Nomikos, P. T. Trzepacz, J.a. Gilmore, M. D. Rotelli, Alan Breier, G. TollefsonAbstract:Objective The objective of this analysis was to compare the treatment-emergent central anticholinergic-like adverse events experienced during treatment with olanzapine versus placebo in patients with psychosis and/or agitation due to Alzheimer's disease (AD). In addition, changes in cognition were assessed in a subgroup of patients with mild to moderate cognitive impairment. Methods Double-blind data were compared for placebo and three fixed olanzapine dosages (5 mg/day, 10 mg/day, and 15 mg/day) in 206 nursing home-residing patients with AD for five a priori selected central nervous system anticholinergic-like adverse events: confusion, delirium, delusions, hallucinations, Abnormal Thinking. Mean change from baseline to endpoint on the Alzheimer's Disease Assessment Scale—Cognitive (ADAS-Cog) was measured for a subgroup of 43 patients who had mild to moderate cognitive impairment at baseline. Results There were no significant differences in central anticholinergic-like adverse events at any olanzapine dose compared to placebo. Additionally, in the 43-patient subgroup, there were no significant differences in mean change in ADAS-Cog scores between placebo and the three olanzapine dose subgroups. Conclusion Olanzapine did not differ significantly from placebo for any of the five central nervous system anticholinergic events nor on the ADAS-Cog. Olanzapine's initially reported potent in vitro muscarinic receptor affinity is not consistent with this clinical study of central nervous system anticholinergic-like adverse events in patients with AD. Copyright © 2001 John Wiley & Sons, Ltd.
-
The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease.
International journal of geriatric psychiatry, 2001Co-Authors: John S. Kennedy, A. Zagar, Franklin Porter Bymaster, George G. Nomikos, P. T. Trzepacz, J.a. Gilmore, M. D. Rotelli, Alan Breier, G. TollefsonAbstract:The objective of this analysis was to compare the treatment-emergent central anticholinergic-like adverse events experienced during treatment with olanzapine versus placebo in patients with psychosis and/or agitation due to Alzheimer's disease (AD). In addition, changes in cognition were assessed in a subgroup of patients with mild to moderate cognitive impairment. Double-blind data were compared for placebo and three fixed olanzapine dosages (5 mg/day, 10 mg/day, and 15 mg/day) in 206 nursing home-residing patients with AD for five a priori selected central nervous system anticholinergic-like adverse events: confusion, delirium, delusions, hallucinations, Abnormal Thinking. Mean change from baseline to endpoint on the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) was measured for a subgroup of 43 patients who had mild to moderate cognitive impairment at baseline. There were no significant differences in central anticholinergic-like adverse events at any olanzapine dose compared to placebo. Additionally, in the 43-patient subgroup, there were no significant differences in mean change in ADAS-Cog scores between placebo and the three olanzapine dose subgroups. Olanzapine did not differ significantly from placebo for any of the five central nervous system anticholinergic events nor on the ADAS-Cog. Olanzapine's initially reported potent in vitro muscarinic receptor affinity is not consistent with this clinical study of central nervous system anticholinergic-like adverse events in patients with AD. Copyright 2001 John Wiley & Sons, Ltd.
W. M. Alves - One of the best experts on this subject based on the ideXlab platform.
-
randomized multicenter dose ranging trial of retigabine for partial onset seizures
Neurology, 2007Co-Authors: Roger J. Porter, A. Partiot, R. Sachdeo, Virinder Nohria, W. M. AlvesAbstract:OBJECTIVE: To evaluate the efficacy and safety of retigabine 600, 900, and 1,200 mg/day administered three times daily as adjunctive therapy in patients with partial-onset seizures. METHODS: A multicenter, randomized, double-blind, placebo-controlled trial was performed. After an 8-week baseline phase, patients were randomized to a 16-week double-blind treatment period (8-week forced titration and 8-week maintenance) followed by either tapering or entry into an open-label extension study. Primary efficacy was the percentage change from baseline in monthly seizure frequency and compared across treatment arms. Secondary efficacy comparisons included the proportion of patients experiencing >/=50% reduction in seizure frequency (responder rate), emergence of new seizure types, and physician assessment of global clinical improvement. Safety/tolerability assessments included adverse events (AEs), physical and neurologic examinations, and clinical laboratory evaluations. Efficacy analyses were performed on the intent-to-treat population. RESULTS: Of the 399 randomized patients, 279 (69.9%) completed the double-blind treatment period. The median percent change in monthly total partial seizure frequency from baseline was -23% for 600 mg/day, -29% for 900 mg/day, and -35% for 1,200 mg/day vs -13% for placebo (p < 0.001 for overall difference across all treatment arms). Responder rates for retigabine were 23% for 600 mg/day, 32% for 900 mg/day (p = 0.021), and 33% for 1,200 mg/day (p = 0.016), vs 16% for placebo. The most common treatment-emergent AEs were somnolence, dizziness, confusion, speech disorder, vertigo, tremor, amnesia, Abnormal Thinking, Abnormal gait, paresthesia, and diplopia. CONCLUSION: Adjunctive therapy with retigabine is well tolerated and reduces the frequency of partial-onset seizures in a dose-dependent manner.
-
Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures
Neurology, 2007Co-Authors: Roger J. Porter, A. Partiot, R. Sachdeo, Virinder Nohria, W. M. AlvesAbstract:Objective: To evaluate the efficacy and safety of retigabine 600, 900, and 1,200 mg/day administered three times daily as adjunctive therapy in patients with partial-onset seizures. Methods: A multicenter, randomized, double-blind, placebo-controlled trial was performed. After an 8-week baseline phase, patients were randomized to a 16-week double-blind treatment period (8-week forced titration and 8-week maintenance) followed by either tapering or entry into an open-label extension study. Primary efficacy was the percentage change from baseline in monthly seizure frequency and compared across treatment arms. Secondary efficacy comparisons included the proportion of patients experiencing ≥50% reduction in seizure frequency (responder rate), emergence of new seizure types, and physician assessment of global clinical improvement. Safety/tolerability assessments included adverse events (AEs), physical and neurologic examinations, and clinical laboratory evaluations. Efficacy analyses were performed on the intent-to-treat population. Results: Of the 399 randomized patients, 279 (69.9%) completed the double-blind treatment period. The median percent change in monthly total partial seizure frequency from baseline was −23% for 600 mg/day, −29% for 900 mg/day, and −35% for 1,200 mg/day vs −13% for placebo ( p p = 0.021), and 33% for 1,200 mg/day ( p = 0.016), vs 16% for placebo. The most common treatment-emergent AEs were somnolence, dizziness, confusion, speech disorder, vertigo, tremor, amnesia, Abnormal Thinking, Abnormal gait, paresthesia, and diplopia. Conclusion: Adjunctive therapy with retigabine is well tolerated and reduces the frequency of partial-onset seizures in a dose-dependent manner.
G.a. Nikpour - One of the best experts on this subject based on the ideXlab platform.
-
Relationship between pain coping strategies with mental disorders symptoms in patients referring to dental clinics
European Psychiatry, 2017Co-Authors: A. Homayouni, R. Ahmadi, G.a. NikpourAbstract:Introduction The study aimed to assess the relationship between mental disorders symptoms with pain coping strategies in dentistry clinics. Method One hundred and twenty people with dental pain that attended in dentistry clinics were randomly selected and responded to Rosenstein and Keefe's Pain Coping Strategies Questionnaire (PCSQ) and Derogatis's Symptom Checklist (SCL-90-R). PCSQ assesses six pain coping strategies: diverting attention, reinterpretation pain sensation, self-negotiation, ignoring pain, disastrous thought, hope–praying, and SCL-90 measures nine dimensions: somatization, obsessive compulsive, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation, and psychoticism. The data were analysed with Pearson correlation coefficient and independent t-test. Results Findings showed positive and significant relationship between disastrous thought with all mental disorders symptoms; and reinterpretation pain sensation with depression and anxiety. Also there is negative significant relationship between ignoring pain with obsessive compulsive, interpersonal sensitivity and somatization; and hope – praying with interpersonal sensitivity, depression, anxiety, paranoid ideation and psychoticism. Meanwhile there were significant differences in males and females. Females got more scores in ignoring pain than males, and males got more scores in anxiety, hostility and paranoid ideation tan females. Discussion With regard to findings, it is recommended that in addition to drug treatment, for changing the attitudes and Thinking in patients with dental pain, psychiatrists and psychologists apply psychological treatments specially cognitive-behavior therapy to reduce Abnormal Thinking level about pain so that the length during of treatment declines, and as a results reduce the personality and health problems that is related with dental pain before and in during of drug treatment.
-
P01-38 Personality, pain, addiction: A new view in pain coping strategies in relation to personality traits in substance abusers
European Psychiatry, 2009Co-Authors: A. Homayouni, A. Khanmohammadi, G.a. Nikpour, M. Ahmadian, S.j. Mosavi AmiriAbstract:Introduction and aim According to recent research about treatment of diseases, pain coping strategies or management of pain can play important role in pain decrease and treatment of disease. But there is a few documented article or reference that imply to pain coping strategies specially in relation to personality in substance abusers. So this pilot study was to assess the relationship between pain coping strategies and personality traits in substance abusers. Method 50 addicted were randomly selected and Rosenstein & Keefe's Pain Coping Strategies Questionnaire (PCSQ) and Mc Care & Costa's NEO PI-R inventory were administered on them. PCSQ assesses six pain coping strategies: diverting attention, reinterpretation pain sensation, self -negotiation, ignoring pain, disastrous thought and praying-hoping and NEO assesses five personality traits: Neuroticism, Extroversion, Agreeableness, Conscientiousness, Openness to experience. Results Finding showedthe are positive significant relationship between neuroticism and disastrous thought, negative significant relationship between agreeableness and disastrous thought, negative significant relationship between neuroticism and diverting attention, positive significant relationship between extroversion and conscientiousness and diverting attention. Discussion With regard to findings it is recomended that in addition to drug treatment, for changing the attitudes and Thinking in addicts, psychiatrits and psychologists apply psychological treatments specially cognitive - behaviour therapy to reduce bad and Abnormal Thinking level about pain so that the lenght during of treatment declince and as a results reduce the personality problems that is related with addiction before and in during drug treatment.
A. Homayouni - One of the best experts on this subject based on the ideXlab platform.
-
Relationship between pain coping strategies with mental disorders symptoms in patients referring to dental clinics
European Psychiatry, 2017Co-Authors: A. Homayouni, R. Ahmadi, G.a. NikpourAbstract:Introduction The study aimed to assess the relationship between mental disorders symptoms with pain coping strategies in dentistry clinics. Method One hundred and twenty people with dental pain that attended in dentistry clinics were randomly selected and responded to Rosenstein and Keefe's Pain Coping Strategies Questionnaire (PCSQ) and Derogatis's Symptom Checklist (SCL-90-R). PCSQ assesses six pain coping strategies: diverting attention, reinterpretation pain sensation, self-negotiation, ignoring pain, disastrous thought, hope–praying, and SCL-90 measures nine dimensions: somatization, obsessive compulsive, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation, and psychoticism. The data were analysed with Pearson correlation coefficient and independent t-test. Results Findings showed positive and significant relationship between disastrous thought with all mental disorders symptoms; and reinterpretation pain sensation with depression and anxiety. Also there is negative significant relationship between ignoring pain with obsessive compulsive, interpersonal sensitivity and somatization; and hope – praying with interpersonal sensitivity, depression, anxiety, paranoid ideation and psychoticism. Meanwhile there were significant differences in males and females. Females got more scores in ignoring pain than males, and males got more scores in anxiety, hostility and paranoid ideation tan females. Discussion With regard to findings, it is recommended that in addition to drug treatment, for changing the attitudes and Thinking in patients with dental pain, psychiatrists and psychologists apply psychological treatments specially cognitive-behavior therapy to reduce Abnormal Thinking level about pain so that the length during of treatment declines, and as a results reduce the personality and health problems that is related with dental pain before and in during of drug treatment.
-
P01-38 Personality, pain, addiction: A new view in pain coping strategies in relation to personality traits in substance abusers
European Psychiatry, 2009Co-Authors: A. Homayouni, A. Khanmohammadi, G.a. Nikpour, M. Ahmadian, S.j. Mosavi AmiriAbstract:Introduction and aim According to recent research about treatment of diseases, pain coping strategies or management of pain can play important role in pain decrease and treatment of disease. But there is a few documented article or reference that imply to pain coping strategies specially in relation to personality in substance abusers. So this pilot study was to assess the relationship between pain coping strategies and personality traits in substance abusers. Method 50 addicted were randomly selected and Rosenstein & Keefe's Pain Coping Strategies Questionnaire (PCSQ) and Mc Care & Costa's NEO PI-R inventory were administered on them. PCSQ assesses six pain coping strategies: diverting attention, reinterpretation pain sensation, self -negotiation, ignoring pain, disastrous thought and praying-hoping and NEO assesses five personality traits: Neuroticism, Extroversion, Agreeableness, Conscientiousness, Openness to experience. Results Finding showedthe are positive significant relationship between neuroticism and disastrous thought, negative significant relationship between agreeableness and disastrous thought, negative significant relationship between neuroticism and diverting attention, positive significant relationship between extroversion and conscientiousness and diverting attention. Discussion With regard to findings it is recomended that in addition to drug treatment, for changing the attitudes and Thinking in addicts, psychiatrits and psychologists apply psychological treatments specially cognitive - behaviour therapy to reduce bad and Abnormal Thinking level about pain so that the lenght during of treatment declince and as a results reduce the personality problems that is related with addiction before and in during drug treatment.
